AWS
KNSA icon

Atria Wealth Solutions’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Atria Wealth Solutions’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,230
Closed -$231K – 2045
2024
Q3 		$231K Buy
+9,230
New +$225K ﹤0.01% 1683

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Atria Wealth Solutions's KNSA Position: Q4 2024 in Review

Atria Wealth Solutions sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2024, closing a stake of 9,230 shares — an estimated $231K sold.

Atria Wealth Solutions first reported a position in KNSA in Q3 2024 and held it in 1 quarter. The position peaked at $231K in Q3 2024. 160 funds tracked by Wall St. Rank hold KNSA as of Q4 2024.

  • Atria Wealth Solutions reported no remaining Kiniksa Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Atria Wealth Solutions sold 9,230 Kiniksa Pharmaceuticals shares in Q4 2024, an estimated $231K.
  • Atria Wealth Solutions first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Atria Wealth Solutions's Kiniksa Pharmaceuticals position peaked at $231K in Q3 2024.
  • 160 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2024.

Based on Atria Wealth Solutions's 13F filing for Q4 2024, filed 31 Jan 2025.